Protection between pregnancies

RhoGAM provides protection by preventing Rh sensitization when administered during every pregnancy.1 Passively acquired anti-D antibodies from RhoGAM may be detectable for several weeks after administration and gradually decline over time.2 Because these antibodies decline, RhoGAM is needed for every Rh-incompatible pregnancy, not just the first.3

Standard protocol for all pregnancies

RhoGAM must be administered during each Rh-incompatible pregnancy in Rh-negative women to help prevent Rh sensitization.1

RhoGAM administration timing remains the same regardless of pregnancy number:

  • 26-28 weeks gestation2,3
  • 72 hours after delivery of an Rh-positive baby2,4

The 300 µg dose administered during pregnancy protects through delivery, but this protection is temporary.2,5 It should be emphasized to patients that previous RhoGAM administration does not eliminate the need for RhoGAM during subsequent Rh-incompatible pregnancies.1

Increased risk factors in subsequent pregnancies

Fetomaternal hemorrhage (FMH) can occur at any point during pregnancy or delivery, allowing fetal red blood cells to enter the maternal circulation and potentially lead to Rh sensitization.6

Multiparous women may have a slightly higher likelihood of obstetric complications that can lead to mixing of maternal and fetal blood.6 The likelihood of FMH increases as pregnancy progresses, particularly near term and during delivery.6 Recognition of these events associated with FMH helps guide appropriate RhoGAM use.3,6,7

Special circumstances in subsequent pregnancies

Certain situations in all pregnancies may require additional consideration or modified protocols.8 These include pregnancies complicated by conditions or procedures that increase the risk of fetomaternal hemorrhage.6,7

If significant fetomaternal hemorrhage is suspected or confirmed through testing, additional RhoGAM doses may be required.3 The standard 300 µg dose protects against approximately 15 mL of Rh-positive red blood cells or 30 mL of fetal whole blood.2 Larger hemorrhages may require dose adjustments to ensure adequate protection.3

Patient education and communication

Common patient concerns about RhoGAM in second pregnancies may include questions about cumulative effects, safety of repeated doses, and necessity of continued treatment. It is important to explain that previous RhoGAM administration does not eliminate the need for it in subsequent Rh-incompatible pregnancies.3

When discussing RhoGAM, it may be helpful to emphasize its routine use and well-established safety profile.1 Since the introduction of RhoGAM in 1968, the incidence of Rh sensitization has decreased.3,5,9